Thrombolytic therapies for ischemic stroke: Triumphs and future challenges

Acute stroke therapy has significantly evolved over the last two decades. The two main advances have been the approval of intravenous chemical thrombolysis in 1995, and the approval of intra-arterial mechanical thrombectomy in 2015. This has led to significant improvement of functional outcomes in a disease known to be the first cause of disability worldwide. Subsequent studies have focused on identifying pre-treatment predictors of good treatment candidates, by developing biochemical and imaging biomarkers. Different doses and agents of thrombolysis are also being tested. In this review article, we explain the fundamentals of stroke therapy focusing on the time, recanalization and collateral perfusion factors. We then review recent advances in stroke thrombolysis, the most significant of which is the recent trials on a novel rtPA agent, tenecteplase, and approval of endovascular treatment as a standard of care. Looking ahead, defining the benefits and limitations of bridging chemical with mechanical thrombolysis is a key area of current interest. This article is part of the Special Issue entitled ‘Cerebral Ischemia’. •This article explains the current fundamentals of acute stroke therapy: Time, recanalization and collaterals.•Alteplase remains the only approved pharmacological treatment for acute stroke, while Tenecteplase is showing promise.•Endovascular treatments with novel devices have revolutionized stroke treatment and greatly improved outcomes.•Biomarkers are being developed to improve patient selection among a growing potential candidates population.